GB2588461A — Use of cannabidiol preparations in the treatment of absence epilepsy

USPTO Abstract

A cannabidiol (CBD) preparation for use in the treatment of absence epilepsy.(TLE). The CBD preparation may comprise greater than or equal to 98% (w/w) CBD and less than or equal to 2% (w/w) other cannabinoids, wherein the less than or equal to 2% (w/w) other cannabinoids comprise the cannabinoids tetrahydrocannabinol (THC); cannabidiol-C1 (CBD-C1); cannabidivarin CBDV); and cannabidiol-C4 (CBD-C4), and wherein the THC is present as a mixture of trans-THC and cis-THC. The CBD present may be isolated from cannabis plant material or at least a portion of at least one of the cannabinoids present in the CBD preparation is isolated from cannabis plant material. The CBD may be present as a synthetic preparation or at least a portion of at least one of the cannabinoids present in the CBD preparation is prepared synthetically. The dose of CBD in the prepartum may be greater than 5 mg/kg/day. The dose of CBD may be 20 mg/kg/day,25 mg/kg/day or 50 mg/kg/day. A method of treating absence epilepsy comprising administering a cannabidiol (CBD) preparation to the subject in need is also disclosed.